Shire plc continuing on Baxalta�s long-standing commitment to the bleeding disorder community, announced the U.S. launch of Vonvendi [von Willebrand...
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). This product may be used in the management of acquired factor VIII deficiency. Prevention and treatment of haemorrhage or surgical bleeding in patients with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.
Baxalta Incorporated announced that the FDA has approved Vonvendi [von Willebrand factor (Recombinant)]. Vonvendi is the first and only recombinant...
Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with Eloctate [antihemophilic factor (recombinant), Fc fusion protein] experienced...
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.
Shire plc announced that the European Commission (EC) has granted Marketing Authorization for Veyvondi [vonicog alfa, recombinant von Willebrand factor]...
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ELOCTA can be used for all age groups.
Sobi (Swedish Orphan Biovitrivum) announced that the FDA has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], a first-in-class, high-sustained factor VIII replacement therapy for adults and children with haemophilia A.
The FDA has approved revised product labeling for Wilate (von Willebrand Factor/Coagulation Factor VIII Complex), from Octapharma, to include prevention...